Baird Financial Group
LGND icon

Baird Financial Group’s Ligand Pharmaceuticals LGND Stock Holding History

Baird Financial Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.7M Sell
8,550
-4,431
-34% -$1.04M ﹤0.01% 994
2026
Q1 		$2.59M Buy
12,981
+158
+1% +$31.3K ﹤0.01% 962
2025
Q4 		$2.42M Buy
12,823
+260
+2% +$50K ﹤0.01% 979
2025
Q3 		$2.23M Sell
12,563
-526
-4% -$78.2K ﹤0.01% 1012
2025
Q2 		$1.49M Buy
13,089
+1,452
+12% +$155K ﹤0.01% 1102
2025
Q1 		$1.22M Sell
11,637
-65,570
-85% -$7.42M ﹤0.01% 1107
2024
Q4 		$8.27M Buy
77,207
+6,143
+9% +$694K 0.02% 557
2024
Q3 		$7.11M Buy
71,064
+14,287
+25% +$1.44M 0.01% 594
2024
Q2 		$4.78M Buy
56,777
+4,467
+9% +$355K 0.01% 678
2024
Q1 		$3.82M Buy
52,310
+12,835
+33% +$946K 0.01% 750
2023
Q4 		$2.82M Sell
39,475
-1,469
-4% -$86.7K 0.01% 833
2023
Q3 		$2.45M Sell
40,944
-2,422
-6% -$159K 0.01% 847
2023
Q2 		$3.13M Buy
43,366
+35,121
+426% +$2.64M 0.01% 776
2023
Q1 		$607K Buy
8,245
+4,684
+132% +$333K ﹤0.01% 1254
2022
Q4 		$238K Sell
3,561
-2,471
-41% -$161K ﹤0.01% 1544
2022
Q3 		$324K Buy
6,032
+104
+2% +$6.11K ﹤0.01% 1434
2022
Q2 		$330K Buy
5,928
+351
+6% +$19.9K ﹤0.01% 1508
2022
Q1 		$391K Sell
5,577
-77
-1% -$5.59K ﹤0.01% 1511
2021
Q4 		$545K Sell
5,654
-1,912
-25% -$177K ﹤0.01% 1440
2021
Q3 		$658K Buy
7,566
+1,481
+24% +$115K ﹤0.01% 1371
2021
Q2 		$498K Sell
6,085
-1,377
-18% -$115K ﹤0.01% 1398
2021
Q1 		$710K Sell
7,462
-239
-3% -$22.6K ﹤0.01% 1256
2020
Q4 		$478K Sell
7,701
-200
-3% -$11.4K ﹤0.01% 1238
2020
Q3 		$470K Sell
7,901
-2,321
-23% -$158K ﹤0.01% 1177
2020
Q2 		$713K Buy
10,222
+1,282
+14% +$81.3K ﹤0.01% 1045
2020
Q1 		$406K Sell
8,940
-2,597
-23% -$147K ﹤0.01% 1121
2019
Q4 		$751K Sell
11,537
-37,574
-77% -$2.51M ﹤0.01% 1059
2019
Q3 		$3.05M Buy
49,111
+1,015
+2% +$63.7K 0.01% 653
2019
Q2 		$3.42M Buy
+48,096
New +$3.54M 0.01% 624

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baird Financial Group's LGND Position: Q2 2026 in Review

Baird Financial Group reduced its Ligand Pharmaceuticals (LGND) stake by 34% in Q2 2026, selling an estimated $1.04M and leaving 8,550 shares worth $2.7M. The position accounts for ﹤0.01% of the portfolio, ranked #994.

Baird Financial Group first reported a position in LGND in Q2 2019 and has held it in 29 quarters since. The position peaked at $8.27M in Q4 2024. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Baird Financial Group held 8,550 shares of Ligand Pharmaceuticals worth $2.7M as of Q2 2026.
  • Baird Financial Group sold 4,431 Ligand Pharmaceuticals shares in Q2 2026, an estimated $1.04M.
  • Ligand Pharmaceuticals made up ﹤0.01% of Baird Financial Group's portfolio in Q2 2026, its #994 holding.
  • Baird Financial Group first reported a position in Ligand Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • Baird Financial Group's Ligand Pharmaceuticals position peaked at $8.27M in Q4 2024.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.